Zobrazeno 1 - 10
of 133
pro vyhledávání: ''
Autor:
Aleksander Giwercman, Gabriella Cohn-Cedermark, Helena Johansson, Stefan Arver, Jakob Eberhard, K. Sandberg, Carina Nord, K. Weibring, Olof Ståhl
Publikováno v:
Annals of Oncology. 30:604-611
BACKGROUND: Little is known regarding sperm production following adjuvant treatment in testicular cancer (TC) clinical stage I (CS I) patients. PATIENTS AND METHODS: A total of 182 TC patients aged 18-50 years were prospectively included during 2001-
Autor:
Gerald W. Prager, S. Moreno Vera, Dirk Arnold, Nadjat Mounedji, Julien Taieb, Antonio Quintela, Alexander Stein
Publikováno v:
Annals of Oncology
Background The optimal chemotherapeutic regimen for use beyond the second line for patients with metastatic colorectal cancer (mCRC) remains unclear. Materials and methods We systematically searched the Cochrane Database of Systematic Reviews, EMBASE
Autor:
Toshio Kubo, A. Morita, N. Yamashita, Tsuneo Shimokawa, S. Ikeo, Kyoichi Kaira, Shunichiro Iwasawa, Shuji Murakami, T. Honda, T. Harada, Naoyuki Nogami, Nobukazu Fujimoto, K. Nakamura, K. Kiura, Akihiro Bessho, Hiroaki Okamoto, Toshihide Yokoyama, Masashi Ishihara
Publikováno v:
Annals of Oncology. 30:ix172-ix173
Background Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (Cb) therapy is one of the standard platinum-containing chemotherapy regimens for patients with advanced non-small cell lung cancer (NSCLC). Adding the anti-vascular endothelial
Autor:
A. Kabashima, Mototsugu Shimokawa, Tsuyoshi Noguchi, Akitaka Makiyama, K. Yuge, Masahito Kotaka, H. Kawanaka, Hideo Baba, Tomomi Kashiwada, Yoshito Akagi, Hiroshi Saeki, Eiji Oki, Keisuke Miwa, Masaki Mori, Yuji Miyamoto
Publikováno v:
Annals of Oncology. 30:v234-v235
Background Elderly patients often cannot tolerate the usual combination of two cytotoxic agents. Recently, bevacizumab plus trifluridine/tipiracil (FTD/TPI) was shown to be a good candidate regimen for vulnerable patients. We aimed to assess the effi
Publikováno v:
Annals of Oncology. 30:v736-v737
Background International guidelines recommend the use of granulocyte colony stimulating factors (G-CSF), such as filgrastim, to prevent chemotherapy-induced febrile neutropenia (FN) and maintain chemotherapy dose to improve clinical outcomes. However
Publikováno v:
Annals of Oncology. 30:ix102
Background Bucco-alveolar carcinoma is a clinical entity prevalent in Asia. These cancers have early involvement of Infra-temporal fossa (ITF) and subsequent poor oncological outcomes. Locally advanced Bucco-alveolar complex carcinoma (T4b) with supr
Autor:
Takashi Egawa, Takafumi Nakano, Hirotoshi Iihara, Osamu Imakyure, Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo
Publikováno v:
Annals of Oncology. 30:ix143
Background The emetogenic classification of antineoplastic agents has provided a framework for defining antiemetic treatment recommendations in international guidelines. The most widely used classification schema identified four emetic risk levels. H
Autor:
D.L. Mitchell, L. Mousa, Dukagjin Blakaj, Ricardo L. Carrau, Sachin R. Jhawar, Amit Agrawal, Brett Klamer, P. Bhateja, Marcelo Bonomi, M. Old, Enver Ozer, Stephen Y. Kang, Mauricio E. Gamez, Jeff Pan, Eric D. Miller, Majd Issa, James W. Rocco, Robert Rupert
Publikováno v:
Annals of Oncology. 30:v457
Background Concurrent chemoradiation (CRT) improves survival in squamous cell carcinoma of the head and neck (HNSCC). Little is known about the outcomes of elderly patients (pts, ≥70 years old) in terms of treatment efficacy and side effects. This
Autor:
Kazuki Ooshima, Tomono Kawase, Masashi Hirota, Tsukasa Tanida, Hiroshi Imamura, Shingo Noura, Takushi Iwazawa, Kouzou Noguchi, Kenzou Akagi, Keizou Douno, Hirotsugu Nagase
Publikováno v:
Annals of Oncology. 30:vi99
Back ground According to the Gastric Cancer Treatment Guidelines, paclitaxel (PTX) plus ramucirumab (RAM) is recommended as second-line treatment for advanced gastric cancer and the regimen included nab-PTX is a conditional recommendation. However, t
Autor:
Tamotsu Sagawa, Masahiro Hirakawa, Koji Miyanishi, Masakazu Hori, Masanori Sato, Koichi Takada, Naotaka Hayasaka, Kensei Nakata, Masanori Someya, Kazuyuki Murase, Koichi Sakata, Junji Kato, Naoki Onoyama, Hiroyuki Ohnuma
Publikováno v:
Annals of Oncology. 30:vi97
Purpose We previously reported early efficacy results from a phase I/II study of definitive chemoradiotherapy using docetaxel, nedaplatin and 5-fluorouracil (DNF-R), and confirmed strong antitumor activity with an acceptable early toxicity profile fo